Skip to main content
Erschienen in: Breast Cancer 4/2010

01.10.2010 | Original Article

The impact of sentinel lymph node biopsy in patients with a core biopsy diagnosis of ductal carcinoma in situ

verfasst von: Wai Ka Hung, Marcus Ying, Miranda Chan, Kong Ling Mak, Lap Kin Chan

Erschienen in: Breast Cancer | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

When ductal carcinoma in situ (DCIS) is found on core biopsy, histological underestimation can occur due to sampling error. When an invasive cancer is subsequently found, another operation is required for nodal staging. Sentinel lymph node biopsy (SLNB) enables nodal staging at the same operation. We examine the value of SLNB in patients with a preoperative diagnosis of DCIS focusing on the need for reoperation.

Methods

Patients with a preoperative core biopsy of DCIS underwent SLNB at the time of definitive surgery. The results of SLNB in relation to histological upstaging were analyzed.

Results

One hundred and seven patients with a core biopsy diagnosis of DCIS underwent simultaneous SLNB at the time of definitive surgery. SLNB was successful in 103 patients (96.3%) and 12 (11.7%) had SLN metastases. Thirty-two patients (29.9%) had histological upstaging and SLN was positive in nine (28.1%). Seventy-five patients had “pure DCIS” but three (4%) had SLN metastases. The presence of a palpable mass and radiological mass lesion were associated with histological upstaging. If SLNB were not performed, 32 patients (29.9%) with upstaging would require another surgery to stage the axilla. In the present series, 84% of these patients had appropriate axillary staging without the need for a second operation.

Conclusion

Underestimation of invasive disease was frequent on core biopsy. Performing SLNB during definitive surgery allowed correct nodal staging in a single operation. SLN metastasis was rare in patients with “pure DCIS” on final pathology. However, additional systemic treatment may be indicated for patients with SLN micrometastases.
Literatur
1.
Zurück zum Zitat Yen T, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–26.CrossRefPubMed Yen T, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–26.CrossRefPubMed
2.
Zurück zum Zitat Pendas S, Dauway E, Giuliano R, Ku NN, Cox CE, Reintgen DS. Sentinel node biopsy in DCIS patients. Ann Surg Oncol. 2000;7:15–20.CrossRefPubMed Pendas S, Dauway E, Giuliano R, Ku NN, Cox CE, Reintgen DS. Sentinel node biopsy in DCIS patients. Ann Surg Oncol. 2000;7:15–20.CrossRefPubMed
3.
Zurück zum Zitat Pendas S, Jakub J, Giuliano R, Gardner M, Swor GB, Reintgen DS. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. Cancer Control. 2004;11(4):231–5.PubMed Pendas S, Jakub J, Giuliano R, Gardner M, Swor GB, Reintgen DS. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. Cancer Control. 2004;11(4):231–5.PubMed
4.
Zurück zum Zitat Hung WK, Chan CM, Ying M, Chong SF, Mak KL, Yip AW. Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg. 2005;92(12):1494–7.CrossRefPubMed Hung WK, Chan CM, Ying M, Chong SF, Mak KL, Yip AW. Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg. 2005;92(12):1494–7.CrossRefPubMed
5.
Zurück zum Zitat Barros AC, Barros MA, Andrade FE, et al. Combined radioguided nonpalpable lesion localization and sentinel lymph node biopsy for early breast carcinoma. Ann Surg Oncol. 2007;14(4):1472–7.CrossRefPubMed Barros AC, Barros MA, Andrade FE, et al. Combined radioguided nonpalpable lesion localization and sentinel lymph node biopsy for early breast carcinoma. Ann Surg Oncol. 2007;14(4):1472–7.CrossRefPubMed
6.
Zurück zum Zitat Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma in situ and ductal carcinoma-in situ with microinvasion? Ann Surg Oncol. 2000;7:636–42.CrossRefPubMed Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma in situ and ductal carcinoma-in situ with microinvasion? Ann Surg Oncol. 2000;7:636–42.CrossRefPubMed
7.
Zurück zum Zitat Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 2001;67:513–9.PubMed Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 2001;67:513–9.PubMed
8.
Zurück zum Zitat Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003;138(3):309–13.CrossRefPubMed Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003;138(3):309–13.CrossRefPubMed
9.
Zurück zum Zitat Wilkie C, White L, Dupont E, Cantor A, Cox CE. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg. 2005;190:563–6.CrossRefPubMed Wilkie C, White L, Dupont E, Cantor A, Cox CE. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg. 2005;190:563–6.CrossRefPubMed
10.
Zurück zum Zitat Zavagno G, Carcoforo P, Marconato R, et al. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer. 2005;5:28.CrossRefPubMed Zavagno G, Carcoforo P, Marconato R, et al. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer. 2005;5:28.CrossRefPubMed
11.
Zurück zum Zitat Camp R, Feezor R, Kasraeian A, et al. Sentinel lymph node biopsy for ductal carcinoma in situ: an evolving approach at the University of Florida. Breast J. 2005;11(6):394–7.CrossRefPubMed Camp R, Feezor R, Kasraeian A, et al. Sentinel lymph node biopsy for ductal carcinoma in situ: an evolving approach at the University of Florida. Breast J. 2005;11(6):394–7.CrossRefPubMed
12.
Zurück zum Zitat Mittendorf EA, Arciero CA, Gutchell V, Hooke J, Shriver CD. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg. 2005;62(2):253–7.CrossRefPubMed Mittendorf EA, Arciero CA, Gutchell V, Hooke J, Shriver CD. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg. 2005;62(2):253–7.CrossRefPubMed
13.
Zurück zum Zitat Tan JC, McCready DR, Easson AM, Leong WL. Role of sentinel lymph node biopsy in ductal carcinoma-in situ treated by mastectomy. Ann Surg Oncol. 2007;14(2):638–45.CrossRefPubMed Tan JC, McCready DR, Easson AM, Leong WL. Role of sentinel lymph node biopsy in ductal carcinoma-in situ treated by mastectomy. Ann Surg Oncol. 2007;14(2):638–45.CrossRefPubMed
14.
Zurück zum Zitat Ansari B, Ogston SA, Purdie CA, Adamson DJ, Brown DC, Thompson AM. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br J Surg. 2008;95(5):547–54.CrossRefPubMed Ansari B, Ogston SA, Purdie CA, Adamson DJ, Brown DC, Thompson AM. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br J Surg. 2008;95(5):547–54.CrossRefPubMed
15.
Zurück zum Zitat Goyal A, Douglas-Jones A, Monypenny I, Sweetland H, Stevens G, Mansel RE. Is there a role of SLNB in DCIS? Analysis of 587 cases. Breast Cancer Res Treat. 2006;98(3):311–4.CrossRefPubMed Goyal A, Douglas-Jones A, Monypenny I, Sweetland H, Stevens G, Mansel RE. Is there a role of SLNB in DCIS? Analysis of 587 cases. Breast Cancer Res Treat. 2006;98(3):311–4.CrossRefPubMed
16.
Zurück zum Zitat Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer. 2006;107(8):1760–8.CrossRefPubMed Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer. 2006;107(8):1760–8.CrossRefPubMed
17.
Zurück zum Zitat Meijnen P, Oldenburg HSA, Loo CE, Nieweg OE, Peterse JL, Rutgers EJT. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg. 2007;94:952–6.CrossRefPubMed Meijnen P, Oldenburg HSA, Loo CE, Nieweg OE, Peterse JL, Rutgers EJT. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg. 2007;94:952–6.CrossRefPubMed
18.
Zurück zum Zitat Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomized trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95:279–93.CrossRefPubMed Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomized trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95:279–93.CrossRefPubMed
19.
Zurück zum Zitat Lagios MD, Silverstein MJ. Sentinel node biopsy for patients with DCIS: a dangerous and unwarranted direction. Ann Surg Oncol. 2001;8:275–7.CrossRefPubMed Lagios MD, Silverstein MJ. Sentinel node biopsy for patients with DCIS: a dangerous and unwarranted direction. Ann Surg Oncol. 2001;8:275–7.CrossRefPubMed
20.
Zurück zum Zitat Moore KH, Thaler HT, Tan LK, Borgen PI, Cody HS. Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact? Cancer. 2004;100:929–34.CrossRefPubMed Moore KH, Thaler HT, Tan LK, Borgen PI, Cody HS. Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact? Cancer. 2004;100:929–34.CrossRefPubMed
21.
Zurück zum Zitat Carter BA, Jensen RA, Simpson JF, Page DL. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol. 2000;113:259–65.CrossRefPubMed Carter BA, Jensen RA, Simpson JF, Page DL. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol. 2000;113:259–65.CrossRefPubMed
Metadaten
Titel
The impact of sentinel lymph node biopsy in patients with a core biopsy diagnosis of ductal carcinoma in situ
verfasst von
Wai Ka Hung
Marcus Ying
Miranda Chan
Kong Ling Mak
Lap Kin Chan
Publikationsdatum
01.10.2010
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 4/2010
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-009-0164-2

Weitere Artikel der Ausgabe 4/2010

Breast Cancer 4/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.